MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


GSK and Alfasigma ink agreement for worldwide rights for linerixibat

ALN

GSK PLC on Monday announced a global licence deal with Alfasigma Spa for the worldwide rights for linerixibat, an investigational treatment for cholestatic pruritus in primary biliary cholangitis.

Under the deal, Bologna, Italy-based pharmaceutical company, Alfasigma, will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat.

In return, London-based pharmaceutical firm GSK will receive $300 million upfront from Alfasigma, and a further $100 million, upon US Food & Drug Administration approval for linerixibat, which is expected before closing based on a March 24 target date.

FTSE 100-listed GSK is also eligible for $20 million on EU and UK approval, up to $270 million in sales-based milestones and tiered double-digit royalties on global net sales.

Linerixibat has been granted orphan drug designation in the US, EU and Japan, and is under regulatory review in multiple markets following positive phase III Glisten trial results. The drug is not yet approved anywhere.

Shares in GSK were down 0.9% at 2,020.40 pence each in London on Monday. The wider FTSE 100 was down 1.7%.

Copyright 2026 Alliance News Ltd. All Rights Reserved.